Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 44 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Nivolumab for adjuvant treatment of stage IB-IIIA non-small cell lung cancer	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Nivolumab for adjuvant and neoadjuvant treatment of localised renal cell carcinoma	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2021	View \| Download
Nivolumab and relatlimab for untreated advanced or metastatic melanoma – first line	Nivolumab (Opdivo; BMS-936558; ONO-4538) , Relatlimab (BMS-986016; Anti-LAG-3)	Melanoma	Skin Cancer	2019	View \| Download
Nivolumab adjuvant therapy for renal cell carcinoma	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2023	View \| Download
Nivolumab adjuvant for treating for stage IIB/IIC resected melanoma	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Melanoma	Skin Cancer	2022	View \| Download
Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Head and neck cancer	Head and Neck Cancer	2017	View \| Download
Nivolumab (Opdivo) in combination with platinum	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Nivolumab (Opdivo) for the treatment of Hepatocellular Carcinoma	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2017	View \| Download
Nivolumab (Opdivo) for Oesophageal Cancer	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Oesophageal cancer	Head and Neck Cancer	2017	View \| Download
Nivolumab (Opdivo) for Melanoma after complete resection of Stage IIIb/c or Stage IV Melanoma (adjuvant therapy)	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Melanoma	Skin Cancer	2017	View \| Download